All data are based on the daily closing price as of October 8, 2025
k

Kaken Pharmaceutical

4521.TSE
24.24 USD
-0.46
-1.86%

Overview

Last close
24.24 usd
Market cap
922.74M usd
52 week high
32.47 usd
52 week low
21.11 usd
Target price
29.78 usd

Valuation

P/E
10.2676
Forward P/E
N/A
Price/Sales
1.5091
Price/Book Value
0.9553
Enterprise Value
584.54M usd
EV/Revenue
0.9496
EV/EBITDA
4.056

Key financials

Revenue TTM
619.55M usd
Gross Profit TTM
381.97M usd
EBITDA TTM
136.18M usd
Earnings per Share
2.39 usd
Dividend
0.98 usd
Total assets
1.22B usd
Net debt
-357.78M usd

About

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins, that are used as fungicides; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, a urinary stone dissolution and elimination acceleration agent for cattle. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001, which is in phase III clinical trial for the treatment of refractory vascular malformations; Seladelpar that is in phase III clinical trial for primary biliary cholangitis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
  • Symbol
    4521.TSE
  • Exchange
    TSE
  • Isin
    JP3207000005
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Tomoyuki Koseki
  • Headquarter
    Tokyo
  • Web site
    https://www.kaken.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top